

Cosmetic Act (21 U.S.C. 321, 351, 352, 353, 355, 360, 371).

§ 341.16 [Amended]

4. Section 341.16 Bronchodilator active ingredients is amended by removing paragraphs (a), (b), (c), and (f) and by redesignating paragraphs (d), (e), and (g) as paragraphs (a), (b), and (c), respectively.

5. Section 341.76 is amended by removing paragraph (c)(5); redesignating paragraph (c)(6) as paragraph (c)(5); and revising the heading for newly redesignated paragraph (c)(5); by removing paragraph (d)(1); by redesignating paragraph (d)(2) as

paragraph (d)(1); by reserving paragraph (d)(2); and by revising the heading in newly redesignated paragraph (d)(1) to read as follows:

§ 341.76 Labeling of bronchodilator drug products.

* * * * *

(c) * * *

(5) For products containing epinephrine, epinephrine bitartrate, or racepinephrine hydrochloride identified in § 341.16(a), (b), and (c). * * *

* * * * *

(d) * * *

(1) For products containing epinephrine, epinephrine bitartrate, or

racepinephrine hydrochloride identified in § 341.16(a), (b), and (c). * * *

(2) [Reserved]

* * * * *

§ 341.90 [Amended]

7. Section 341.90 *Professional labeling* is amended by removing paragraph (a) and redesignating paragraphs (b) through (q) as paragraphs (a) through (p), respectively.

Dated: July 5, 1995.

William K. Hubbard,

Acting Deputy Commissioner for Policy.

[FR Doc. 95-18448 Filed 7-26-95; 8:45 am]

BILLING CODE 4160-01-F